HOME >> BIOLOGY >> NEWS
More chance of a cure for patients with common and aggressive form of blood cancer

Two year follow up from pivotal study shows benefit of using MabThera plus CHOP chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma (NHL)

Orlando, Florida, 10 December 2001 - Patients with an aggressive form of blood cancer, non-Hodgkin's lymphoma, can increase their chance of a cure with the new drug combination MabThera (rituximab) plus CHOP (standard chemotherapy), compared to standard chemotherapy alone. This is according to two year results from the pivotal GELA study presented today at the American Society of Hematology (ASH).

Based on these updated results it is estimated that after a median follow up of almost 26 months, 70% of patients treated with the MabThera plus CHOP combination will be alive and well, compared to 57% after standard chemotherapy alone. Current medical opinion indicates that if patients survive past the two-year milestone their chances of a cure can be up to 90% .

Lead investigator for the GELA study, Professor Bertrand Coiffier, head of the Department of Hematology, Hospices Civiles de Lyon, France said: "This is the first new drug combination in more than 20 years to show an improvement in overall survival for patients with aggressive non-Hodgkin's lymphoma (NHL), a rapidly fatal form of the cancer. This is a real breakthrough for NHL sufferers around the world."

The MabThera plus CHOP combination is also effective in treating another form of the disease known as indolent, or low grade NHL. Dr Myron Czuczman's data on the six year follow-up of patients with indolent NHL, treated with MabThera plus CHOP showed that 55% of the patients are still in remission at almost four years (46.8 months) and up to seven years (86.3 months). All patients treated responded (58% complete response and 42% partial response) and the overall response rate in patients who completed therapy was 100% (63% complete response and 37% partial response).

Approximately 1.5 million peopl
'"/>

Contact: Rina Amin
rina.amin@ketchum.com
44-20-7611-3513
Ketchum
10-Dec-2001


Page: 1 2

Related biology news :

1. Egg-sharing does not damage a donors own chance of a baby say UK researchers
2. Fat chance for hosts
3. Pachinko chances
4. Quarries may be last chance for many rare European butterflies
5. Doctors miss chances to help pregnant women quit smoking
6. Best chance to protect giant pandas
7. Stanford research points to chance as cause of genetic diseases in Ashkenazi Jews
8. Normal gene control increases chances human stem cells will be safe
9. Smoking decreases mens chances of fatherhood by IVF and ICSI
10. Sunlight, PCB exposure enhance skin cancer chances
11. Doctors miss chance to advise women of vitamin that prevents birth defects, survey finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2020)... ... March 02, 2020 , ... Philadelphia IP law firm Panitch Schwarze ... has joined the firm as a Partner, and Stephany G. Small, Ph.D., has joined ... attorney and will be a partner in the firm’s biotechnology and life science practice ...
(Date:2/28/2020)... ... February 26, 2020 , ... ... PRP™ and Rebound PRF® devices are now available to veterinary practices through ... medical devices, that will provide the most affordable, easiest to use, multi-species ...
(Date:2/28/2020)... ... February 28, 2020 , ... Regen Suppliers ... This includes all available stem cell and exosome biologics. , Regen Suppliers offers ... Biologics, PRP kits, adipose kits, PDO thread lifts and more. The company ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... ... to improve their manufacturing operations in order to adapt to new approaches like ... up with the increasing demand for personalized medicine and therapies. But with an ...
(Date:2/11/2020)... , ... February 11, 2020 ... ... is pleased to announce the successful results from a long-term follow-up clinical ... the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block design, the ...
(Date:2/3/2020)... ... February 03, 2020 , ... Ovation Travel ... Firm Travel, Technology Industry Travel and Biotech/Healthcare Industry Travel Indexes. , All of ... the following statistics:, Average airfare price paid Domestically, ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cerebyte, the leader ... mobile computing, today announced the availability of neuroscience of transformational leadership workshops. These ... latest neuroscience of leadership and change research to become great transformational leaders. The ...
Breaking Biology Technology:
Cached News: